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Contrasting effects of ﬂuoroquinolone antibiotics
on the expression of the collagenases, matrix
metalloproteinases (MMP)-1 and -13,
in human tendon-derived cells
A. N. Corps, R. L. Harrall, V. A. Curry, B. L. Hazleman and G. P. Riley
Objectives. Fluoroquinolone antibiotics may cause tendon pain and rupture. We reported previously that the ﬂuoroquinolone
ciproﬂoxacin potentiated interleukin (IL)-1b-stimulated expression of matrix metalloproteinases (MMP)-3 and MMP-1 in
human tendon-derived cells. We have now tested additional ﬂuoroquinolones and investigated whether they have a similar effect
on expression of MMP-13.
Methods. Tendon cells were incubated for two periods of 48 h with or without ﬂuoroquinolones and IL-1b. Total ribonucleic
acid (RNA) was assayed for MMP messenger RNA by relative quantitative reverse transcriptase polymerase chain reaction,
with normalization for glyceraldehyde-3-phosphate dehydrogenase mRNA. Samples of supernatant medium were assayed for
MMP output by activity assays.
Results. MMP-13 was expressed by tendon cells at lower levels than MMP-1, and was stimulated typically 10- to 100-fold by
IL-1b. Ciproﬂoxacin, norﬂoxacin and oﬂoxacin each reduced both basal and stimulated expression of MMP-13 mRNA.
In contrast, ciproﬂoxacin and norﬂoxacin increased basal and IL-1b-stimulated MMP-1 mRNA expression. Both the inhibition
of MMP-13 and the potentiation of MMP-1 expression by ﬂuoroquinolones were accompanied by corresponding changes in
IL-1b-stimulated MMP output. The non-ﬂuorinated quinolone nalidixic acid had lesser or no effects.
Conclusions. Fluoroquinolones show contrasting effects on the expression of the two collagenases MMP-1 and MMP-13,
indicating speciﬁc effects on MMP gene regulation.
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The ﬂuoroquinolones are a widely used group of broad-spectrum
antibiotics which target prokaryotic deoxyribonucleic acid
(DNA) gyrase. Among other, generally mild, side-effects [1–4],
ﬂuoroquinolones may induce tendon pain and rupture in a small
proportion (less than 1%) of patients, an effect most frequently
described for the Achilles tendon [5–7]. The factors predisposing
individuals to suffer tendon damage remain undeﬁned, although
age, activity levels and ongoing treatment with corticosteroids have
each been implicated [5–8]. Different clinical studies have reported
a predominance of tendon problems with different members of
the ﬂuoroquinolone group (peﬂoxacin, ciproﬂoxacin, oﬂoxacin
etc.), but the action on tendon appears to be a class effect [5–8].
Several studies suggest that alterations in the synthesis or
breakdown of extracellular matrix (ECM) components may
contribute to ﬂuoroquinolone-induced tendon damage [9–12].
Treatment of rodents with peﬂoxacin produced a biphasic change
in Achilles tendon proteoglycan synthesis, and oxidative damage
to tendon collagen [11]. Both collagen irregularity and increased
interﬁbrillar proteoglycan were described in a histopathological
examination of a ciproﬂoxacin-associated Achilles tendinopathy
[13]. In vitro studies indicated that increased expression of protease
(caseinase) activity occurs in ﬂuoroquinolone-treated cultured
canine tenocytes [10], and we showed that ciproﬂoxacin poten-
tiated the output of matrix metalloproteinase (MMP)-3 by
interleukin (IL)-1-stimulated human tenocytes and increased
the expression levels of both MMP-3 and collagenase 1 (MMP-1)
messenger ribonucleic acid (mRNA) [12]. In the present study
we have tested whether ﬂuoroquinolones also affect the expression
of a second IL-1-stimulated collagenase, MMP-13.
Materials and methods
Materials
Ciproﬂoxacin was obtained from ICN (Basingstoke, UK).
Norﬂoxacin, oﬂoxacin, nalidixic acid and TRI-Reagent were
from Sigma (Poole, UK). Fluoroquinolones were freshly dissolved
at 10mg/ml in 0.1M HCl, while nalidixic acid was dissolved at
10mg/ml in 0.1M NaOH. Interleukin-1 was a gift from Glaxo
Wellcome (Stevenage, UK). Dulbecco’s Modiﬁed Eagle Medium
(DMEM), fetal calf serum (FCS), antibiotics and oligonucleotide
primers for reverse transcriptase polymerase chain reaction
(RT-RCR) were obtained from Invitrogen (Paisley, UK).
One-Step RT-PCR reagents and ﬂuorescein (FAM)-labelled
oligonucleotide probes were obtained from Applied Biosystems
(Warrington, UK).
Achilles tendon specimens were obtained from tissue discarded
during surgery, with approval by the Cambridge Local Research
Ethics Committee and written consent from informed patients.
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Cell isolation and incubation
The isolation of tendon cells by outgrowth from tendon explants
was described previously [12]. Cells (at passages between 4 and 10)
were seeded at 105 cells/well in six-well plates and were incubated
for 3 days before the experiment. Cells were rinsed with 2ml of
serum-free DMEM containing insulin, transferrin and selenium
(ITS), and were given 2ml of the same medium containing
ﬂuoroquinolones (50g/ml) as required; control cells received
equivalent additions of 0.1M HCl or NaOH (1% v/v, which
did not signiﬁcantly alter the pH of the medium). After 48 h the
cells were rinsed and were given fresh medium with the same
ﬂuoroquinolone or control addition as in the pre-treatment,
each with or without IL-1 (1 ng/ml). After further incubation
for 48 h the supernatant medium was removed and stored at
20C, and the cells were rinsed with balanced salts solution and
solubilized in TRI-Reagent (1ml/well).
This experimental design (48 h pre-incubation with ﬂuoro-
quinolones, followed by 48 h incubation with or without IL-1
in the continuing presence of ﬂuoroquinolones) was adopted for
consistency with our previous work showing potentiation of
MMP-3 and MMP-1 expression [12]. We have found that
a reduced, more variable, potentiation was obtained if the
pre-incubation time was reduced and ciproﬂoxacin was added
only at the same time as IL-1. Similarly, although the effects
of ﬂuoroquinolones described below were evident by 6 h of
incubation with IL-1 in some experiments and by 24 h in each
experiment, we have reported the data obtained after 48 h
incubation for consistency.
RNA isolation and analysis by RT-PCR
Ribonucleic acid was isolated from the TRI-Reagent extracts
by phenol-chloroform separation followed by precipitation
with isopropanol and ethanol. The RNA was stored as aliquots
at 70C, and was assayed using One-Step RT-PCR in a
GeneAmp 5700 (Applied Biosystems). All samples from a single
experiment were run on the same plate, using either two or
three replicate determinations per sample. The values obtained for
MMP mRNA expression were corrected for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA expression in the
same sample.
The primers and probes for GAPDH, MMP-1 and MMP-13
have been described previously [14, 15]. Standard curves were
run in each assay, using freshly diluted aliquots of pooled tendon
cell RNA. For each target this produced a linear plot of threshold
cycle (Ct) against log(dilution), whose slope was within 10% of
the expected value, indicating a similar, near-maximum efﬁciency.
A single product of the appropriate size was produced, and no
signal was produced if either the RNA or the reverse transcriptase
step was omitted.
Assays of MMP-1 and MMP-13 activity
Serum-free culture supernatants were assayed for MMP-1 and
MMP-13 using speciﬁc Fluorokine E ﬂuorimetric assays as
described by the supplier (R&D Systems, Abingdon, UK).
Samples with high MMP-1 content were diluted with assay
diluent if required. Samples for MMP-13 assay were concentrated
5-fold using Centricon-10 concentrators (Millipore, Watford,
UK). All samples were treated with 4-aminophenylmercuric
acetate (APMA) to activate pro-enzyme prior to the assay, so
that the total (latent and active) enzyme could be detected.Without
APMA very little activity was recorded, consistent with our
demonstration that most of the MMP-1 secreted by these cells
was in the pro-enzyme form [12].
Presentation of data
The results presented are from ﬁve experiments performed
separately with cells derived from ﬁve separate donors, in serum-
free medium as described above. Similar results were obtained
in parallel incubations in medium containing 10% FCS (data not
shown), and aspects of the data for ciproﬂoxacin have been
conﬁrmed in at least six additional experiments. For data showing
the effects of ﬂuoroquinolones on basal MMP mRNA expression,
the expression in control cells in each experiment was deﬁned
as 100%. For data showing the effects of ﬂuoroquinolones on
IL-1-stimulated MMP mRNA expression, the expression in cells
treated with IL-1 alone (after a control pre-incubation) was
deﬁned as 100%, consistent with our previous report [12].
Signiﬁcant differences from the 100% value were assessed using
the 95% and 99% conﬁdence intervals of the treated samples, and
are presented in the ﬁgures as P<0.05 (*) and P<0.01 (**).
Results
Tendon cells expressed mRNA encoding the collagenases MMP-1
and MMP-13. Basal expression of MMP-13 mRNA was at least
100-fold lower than that of MMP-1, as estimated from the Ct
values in the optimized RT-PCR assays. Incubation of the cells
with each of the ﬂuoroquinolones and nalidixic acid reduced
the basal expression of MMP-13 mRNA (Fig. 1A). Ciproﬂoxacin
had the most consistent effects, and reduced MMP-13 mRNA
expression in ﬁve out of six further experiments in addition to those
shown in Fig. 1A. Interleukin-1 stimulated MMP-13 mRNA
expression, typically 10- to 100-fold. Each of the ﬂuoroquinolones
also caused a signiﬁcant reduction in MMP-13 mRNA expression
in IL-1-stimulated cells (Fig. 1C), although it should be noted
that IL-1 retained the ability to stimulate the expression of
MMP-13 mRNA in the presence of ﬂuoroquinolones. Nalidixic
acid had no consistent effect on IL-1-stimulatedMMP-13 mRNA
expression (Fig. 1C).
Interleukin-1 also stimulated MMP-1 mRNA expression,
typically 100-fold. In marked contrast to their effects on MMP-13
mRNA, both ciproﬂoxacin and norﬂoxacin enhanced both basal
and IL-1-stimulated expression of MMP-1 mRNA, while oﬂox-
acin and nalidixic acid had lesser or no effect (Figs 1B, 1D). This
was observed both in serum-free medium (Fig. 1) and in medium
containing 10% FCS; in the latter, oﬂoxacin had a smaller effect
than ciproﬂoxacin or norﬂoxacin on basal MMP-1 expression,
whereas ciproﬂoxacin had a greater effect than norﬂoxacin
or oﬂoxacin on IL-1-stimulated MMP-1 expression (P<0.05 by
Wilcoxon matched pairs test; n¼ 7; data not shown).
The contrasting effects of ﬂuoroquinolones on MMP-1 and
MMP-13 mRNA expression were generally reﬂected in MMP
output, measured by activity assays on the culture supernatants
(Fig. 2). Interleukin-1-stimulated output of MMP-13 protein
could be detected only after concentrating the culture super-
natants, and corresponded to between 20 and 200 pg/ml over 48 h
of stimulation by IL-1, compared with typically 40 ng/ml
MMP-1 in the same samples. Ciproﬂoxacin and norﬂoxacin
reduced MMP-13 output (Fig. 2A) and increased MMP-1 output
(Fig. 2B). Oﬂoxacin or nalidixic acid had no signiﬁcant effects
(Fig. 2). We reported previously that ciproﬂoxacin did not
consistently potentiate IL-1-stimulated MMP-1 output when
assayed by western blotting [12]. However, such a potentiation of
MMP-1 output by ciproﬂoxacin has been observed in the majority
of subsequent experiments, although (as in the earlier work [12])
it has been smaller than the potentiation of MMP-3 expression in
the same experiments. Thus, western blots of MMP-1 output in
the present experiments showed a small potentiation of MMP-1
output by ciproﬂoxacin and norﬂoxacin that was consistent
with the MMP-1 activity reported in Fig. 2B (V. A. Curry and
A. N. Corps, data not shown).
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Discussion
Tendon damage and rupture is a signiﬁcant side-effect in a small
proportion of patients treated with ﬂuoroquinolones [5–8], and
various studies have indicated that there are irregularities in
ECM turnover in ﬂuoroquinolone-treated patients and animal
models [9, 11, 13]. Here we have found that the ﬂuoroquinolones
ciproﬂoxacin and norﬂoxacin increase and decrease, respectively,
the expression of the collagenases MMP-1 and MMP-13.
Expression of MMP-13 was markedly lower than that of MMP-1
in this culture system, but we cannot predict which of these
contrasting effects of ﬂuoroquinolones would be the more
signiﬁcant for collagenase expression or activity in the mechanical
environment of the tendon in vivo.
Although we initially detected ﬂuoroquinolone effects on
MMP expression in the context of IL-1-stimulated expression
of MMP-3 [12], several lines of evidence now indicate that their
effects are independent of IL-1 receptors or IL-1 receptor-
mediated signal transduction. First, ﬂuoroquinolones affect
basal expression of MMP-1 and MMP-3 (Fig. 1 and [12]), a result
consistent with an earlier observation of increased protease
activity from canine tendon cells [10]; they also have similar effects
on the stimulation of these MMP induced by other growth
factors (R. L. Harrall and A. N. Corps, unpublished data).
Second, although they reduce the expression of MMP-13 they
do not prevent stimulation by IL-1 above the reduced basal
level (Figs 1 and 2). Third, ciproﬂoxacin did not affect
early phosphorylation responses to IL-1 or its induction of
cyclooxygenase-2 [16].
Further work will be required to deﬁne the molecular site(s)
of action of the ﬂuoroquinolones. Although ﬂuoroquinolones
decreased IL-1-stimulated output of prostaglandin (PG) E2,
this did not explain the potentiation of MMP expression [16].
Recent studies using a rabbit tendon-derived cell line showed
that oﬂoxacin was less effective than ciproﬂoxacin in generating
reactive oxygen species (ROS) [17]. Those authors raised the
possibility that ROS might be involved in the mechanism by which
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FIG. 1. Expression of MMP-13 and MMP-1 mRNA in human tendon-derived cells. Control cells (con) or cells pre-treated
with 50g/ml ciproﬂoxacin (cip), oﬂoxacin (oﬂ), norﬂoxacin (nor) or nalidixic acid (nal), were then incubated for 48 h with
the same ﬂuoroquinolone or control addition as in the pre-treatment, each with or without IL-1 (1 ng/ml). (A) MMP-13 and
(B) MMP-1 mRNA in cells treated with ﬂuoroquinolones alone were expressed relative to that in control unstimulated cells
(deﬁned as 100%). (C) MMP-13 and (D) MMP-1 mRNA were expressed relative to that in IL-1-stimulated cells after control
pre-treatment (deﬁned as 100%). Open columns, unstimulated cells; ﬁlled columns, IL-1-stimulated cells. Mean±S.E.M. from ﬁve
experiments.
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FIG. 2. Output of MMP-13 and MMP-1 from human tendon-
derived cells. Control cells (con) or cells pre-treated with
50g/ml ciproﬂoxacin (cip), oﬂoxacin (oﬂ), norﬂoxacin (nor)
or nalidixic acid (nal) were then incubated for 48 h with
the same ﬂuoroquinolone or control addition as in the
pre-treatment, each with or without IL-1 (1 ng/ml). (A)
MMP-13 and (B) MMP-1 activity in supernatant medium
from IL-1-stimulated cells (ﬁlled columns) was expressed
relative to that in medium from IL-1-stimulated cells after
control pre-treatment (deﬁned as 100%). Mean±S.E.M. from
three experiments. The values in the unstimulated cells (with
or without ﬂuoroquinolone treatment) ranged between undetect-
able and 5% of those in the IL-1-stimulated cells (data not
shown).
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ﬂuoroquinolones increase expression of MMP [17], and the similar
relative potencies of ciproﬂoxacin and oﬂoxacin in both their study
and ours are consistent with that hypothesis, which remains to be
tested. The contrasting effects of ﬂuoroquinolones on expression
of MMP-1 and -13 implies that they may differentially affect one
or more transcription factors which interact at the promoters of
the MMP genes, for example AP1 or NFB [18]. Using electro-
phoretic mobility shift assays, we have not detected effects of
ciproﬂoxacin on either the basal or IL-1-stimulated activity
of either of these factors in tendon cell extracts (A. N. Corps,
unpublished data). An alternative approach would be to examine
the effect of ﬂuoroquinolones on the expression of transfected
reporter plasmids driven by the MMP-1 and MMP-13 gene
promoters, focusing on regions showing potential differences
between the two promoters.
It is not clear how the order of ﬂuoroquinolone potency that we
have observed in vitro (ciproﬂoxacin and norﬂoxacin generally
being more potent than oﬂoxacin) relates to clinical tendon
problems. In a rat model of ﬂuoroquinolone-induced tendon
lesions, oﬂoxacin was more effective than ciproﬂoxacin and
norﬂoxacin [19]. Clinical studies have often highlighted different
individual ﬂuoroquinolones [5–7], but, in a study presenting the
adjusted odds ratios for Achilles tendon rupture in the elderly,
the 95% conﬁdence intervals for oﬂoxacin, ciproﬂoxacin and
norﬂoxacin overlapped [8]. Given that the ﬂuoroquinolones may
affect the expression of different genes in opposite directions,
as shown here, and that ﬂuoroquinolones have been reported to
affect the expression of other genes, such as those for cytokines [4],
it is likely that altered MMP expression may be one of several
factors contributing to tendon damage.
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Key messages
 Fluoroquinolone antibiotics show
differential effects on the expression of
collagenases by tendon cells. These
may contribute to the tendon problems
experienced by some ﬂuoroquinolone-
treated patients.
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